Progenics Pharmaceuticals Inc (NASDAQ:PGNX)
| 4.06 Data as of May 23 |  +0.15 / +3.84%Today’s Change | 1.41 Today|||52-Week Range 11.00 | +36.24% Year-to-Date |
Latest PGNX News | Press Releases
| Salix Beats on Earnings - Analyst Blog May 14 / Zacks.com |
Today’s Trading
| Previous close | 3.91 |
| Today’s open | 3.86 |
| Day’s range | -- - -- |
| Volume | 189,506 |
| Average volume (3 months) | 478,389 |
| Market cap | $207.2M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | -429.03% |
| Earnings growth (this year) | +7.52% |
| Earnings growth (next 5 years) | +7.00% |
| Revenue growth (last year) | -81.74% |
| P/E ratio | NM |
| Price/Sales | 7.37 |
| Price/Book | 2.84 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SUPNSupernus Pharmaceuti... | +0.05 | +0.76% |
| VNDAVanda Pharmaceutical... | +0.15 | +2.15% |
| --Genufood Energy Enzy... | 0.00 | 0.00% |
| GALEGalena Biopharma Inc | +0.02 | +0.78% |
Data as of 4:00pm ET, 05/23/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.23 |
| Annual revenue (last year) | $14.0M |
| Annual profit (last year) | -$35.4M |
| Net profit margin | -252.21% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mark Robert Baker |
CFO, Treasurer, Chief Accounting Officer & VP Angelo William Lovallo, Jr., CPA |
Corporate headquarters Tarrytown, New York |
Forecasts
